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Abstract
Background: In view of the increasing pressure on the UK’s maternity units, new methods of labour induction are
required to alleviate the burden on the National Health Service, while maintaining the quality of care for women
during delivery. A model was developed to evaluate the resource use associated with misoprostol vaginal inserts
(MVIs) and dinoprostone vaginal inserts (DVIs) for the induction of labour at term.
Methods: The one-year Markov model estimated clinical outcomes in a hypothetical cohort of 1397 pregnant
women (parous and nulliparous) induced with either MVI or DVI at Southmead Hospital, Bristol, UK. Efficacy and
safety data were based on published and unpublished results from a phase III, double-blind, multicentre, randomised
controlled trial. Resource use was modelled using data from labour induction during antenatal admission to patient
discharge from Southmead Hospital. The model’s sensitivity to key parameters was explored in deterministic multi-way
and scenario-based analyses.
Results: Over one year, the model results indicated MVI use could lead to a reduction of 10,201 h (28.9 %) in the time
to vaginal delivery, and an increase of 121 % and 52 % in the proportion of women achieving vaginal delivery at 12
and 24 h, respectively, compared with DVI use. Inducing women with the MVI could lead to a 25.2 % reduction in the
number of midwife shifts spent managing labour induction and 451 fewer hospital bed days. These resource utilisation
reductions may equate to a potential 27.4 % increase in birthing capacity at Southmead Hospital, when using the MVI
instead of the DVI.
Conclusions: Resource use, in addition to clinical considerations, should be considered when making decisions about
labour induction methods. Our model analysis suggests the MVI is an effective method for labour induction, and could
lead to a considerable reduction in resource use compared with the DVI, thereby alleviating the increasing burden of
labour induction in UK hospitals.
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Maternity services in the UK National Health Service
(NHS) face considerable pressure to manage births–the
birth rate in England is currently at its highest since
1971 [1, 2], and is increasing [3]. This coincides with UK
NHS resources being cut; spending on maternity services
decreased in half the geographical regions in England
from 2012 to 2013 [2]. Over one third of senior midwives
report insufficient budgets to support recommended mini-
mum staffing levels [4]. The average annual number of
births per midwife in the UK widely exceeds the recom-
mended ratio of 29.5 to 1 [5], potentially impacting the
quality and efficiency of care [2, 5].
Labour induction rates have also risen in recent decades
[6]. Induction is typically recommended when pregnancy
continuation is associated with maternal and fetal health
risks [6–8]; in the UK, approximately one fifth of de-
liveries are induced due to safety concerns for the
mother and/or fetus [9]. Vaginally-administered dino-
prostone is recommended for cervical ripening prior
to labour induction in the UK, augmented with oxy-
tocin as required [7, 8]. Dinoprostone-based products
are effective, but may require considerable resources
[10]. One third of women induced using the dinoprostone
vaginal insert (DVI; Propess®) deliver vaginally within 24 h
of induction, with the remainder experiencing prolonged
onset and duration of labour [11]. Furthermore, three
quarters of inductions with the DVI require augmentation
with oxytocin [11]; on average, oxytocin administration
entails 14 h [12] of continuous monitoring by a healthcare
professional [8].
Misoprostol tablets are sometimes used off-label to
induce labour as it is thought that a shorter time to
delivery (compared to dinoprostone) can be achieved.
However, misoprostol tablets are not licensed for use
in labour induction [13–18] and the evidence to support
this method of induction is sparse [19, 20]. For example,
national recommendations and guidelines mention use of
misoprostol tablets, but only in the setting of a clinical
trial [13, 14, 17]. Thus, while misoprostol may offer effect-
ive means of labour induction, off-label use is associated
with a range of issues for healthcare providers, including
inaccurate dosing due to tablet splitting [21, 22], the need
to obtain informed consent [23, 24] and the potential risk
of litigation [25, 26].
The misoprostol vaginal insert (MVI; Misodel™) −
approved for labour induction − is a single-application,
controlled-release, retrievable system that ripens the
cervix and promotes uterotonic activity. In the EXPEDITE
study [11], a phase III randomised controlled trial includ-
ing 1358 women comparing the MVI (200 μg) to the DVI
(10 mg), the MVI reduced median time to vaginal delivery
by 11 h relative to the DVI. These reductions led to
a statistically-significant increase in the proportion ofvaginal deliveries occurring within 24 h, from 34 % to
55 % (p < 0.001). This increase may be clinically relevant,
as longer labours are more likely to be associated with
maternal infection than shorter labours [27]. Additionally,
fewer women required oxytocin during delivery when
induced with the MVI compared with the DVI, and −
among those who needed it − administration duration was
reduced by three hours [11].
The MVI was associated with an increase in intrapar-
tum adverse events (AEs) necessitating medical attention
compared with the DVI [11]. Uterine tachysystole requir-
ing intervention occurred in 1.9 % and 0.6 % of
women receiving the MVI and the DVI, respectively
(unpublished observations from the clinical report of
the EXPEDITE study). The MVI and the DVI were
associated with similar rates of treatment-related neo-
natal intensive care unit (NICU) admissions (0.6 % vs
0.1 %, respectively), and caesarean sections (26.0 % vs
27.1 %, respectively; P =NS) [11].
Using efficacy and safety data reported in the EXPEDITE
study, the objective of this study was to develop a model-
based analysis to estimate and compare healthcare resource
use associated with labour induction using the MVI instead
of the DVI from a UK NHS hospital perspective.
Methods
A model was developed in Microsoft® Excel® to estimate
the time and resource use associated with labour induc-
tion using the MVI compared with the DVI. This was
based on Southmead Hospital in Bristol, UK, using actual
clinical data from this hospital collected between March
2013 and February 2014 as the basis for the model’s pa-
tient population, parity distribution and resource use. The
model estimated resource utilisation during i) pre-active
labour (the time from labour induction to onset of active
labour), ii) active labour (the time from onset of active
labour to delivery); iii) delivery (spontaneous or assisted
vaginal delivery, or caesarean section); iv) inpatient stay
(time from delivery to patient discharge from the hos-
pital), using published [11] and unpublished safety and
efficacy data from the EXPEDITE study. All unpublished
clinical data from the EXPEDITE study used in the model
were sourced from the associated clinical study report.
AEs associated with labour induction were also estimated,
based on treatment-related events reported in the
EXPEDITE study. Ethics approval was not obtained as this
is not applicable to this analysis. Permission to use non-
patient-specific clinical data was provided by Southmead
hospital–individual clinical records were not directly
accessed as part of our analysis.
By allowing flexibility in cycle length, a Markov struc-
ture (Fig. 1)–in which women’s outcomes and the associ-
ated costs depended on their previous state and the
probability of transitioning to a different state–provided
Fig. 1 Model structure
Draycott et al. BMC Health Services Research  (2016) 16:49 Page 3 of 9sufficient sensitivity to account for variations in the
duration of labour. A cycle length of one hour was
assumed to ensure sufficient accuracy in capturing
differences between the efficacy and safety profiles of
the two treatments.
Time-dependent probability estimates, based on unpub-
lished Kaplan-Meier data from the EXPEDITE study, were
used to model the progression of a hypothetical cohort of
women induced with the DVI or the MVI through differ-
ent stages of labour, as these probabilities were not estim-
able using median values from the published data [11].
The model assumed that different methods of labour
induction were mutually exclusive and that all women
entering the model received only one of the two labour
induction methods. The model did not address expectant
management, nor mechanical means of induction–such as
the use of Foley catheters–which have been shown to be
less effective in parous women than in nulliparous women
[28], and are not recommended for labour induction in
the UK [8]. Onset of labour and delivery were assumed to
be a function of the time since induction, based on unpub-
lished Kaplan-Meier data from the EXPEDITE study.
Other probabilities (e.g. the proportion of women
requiring oxytocin and the proportion of women ex-
periencing individual AEs) were assumed to remain
constant over time. As several AEs may occur over the
duration of a single labour and delivery, the model re-
ported overall rates of treatment-related AEs rather than
the proportion of women and neonates experiencing indi-
vidual AEs. The incidence of AEs across nulliparous
women, parous women and neonates, as reported in the
EXPEDITE study, was applied to the overall cohort of
women modelled. The clinically-relevant AEs (from the
perspective of both mother and child) included in the
model, based on EXPEDITE study data, were uterine
tachysystole (with and without fetal heart rate in-
volvement), postpartum haemorrhage, meconium-stained
liquor, neonatal intensive care unit (NICU) admission,
Apgar score greater than seven at five minutes, uterine
rupture and neonatal acidosis [11].Model parameters representing the number of deliveries
and hospital management resource use were based on
actual clinical data from the NHS Southmead Hospital in
Bristol, UK, spanning one year from March 2013 to
February 2014 (unpublished observations). During this
one-year period, 6140 births were reported, of which
1397 (22.8 %) were induced; of the women induced,
741 (53.0 %) and 656 (47.0 %) were parous and nullipar-
ous, respectively. Aside from these, other demographics of
the model cohort were thus assumed identical to that of
the population of the EXPEDITE study [11]. The model
compared labour induction in a hypothetical cohort of
1397 women over one year with the DVI in the current
treatment pattern, to a revised treatment pattern in which
the entire cohort was instead induced using the MVI.
Model outcomes included the proportion of women
requiring oxytocin and duration of oxytocin use, time to
vaginal delivery, caesarean section or any delivery, number
of staff shifts and bed hours, capacity for additional induc-
tions on the ward, and frequency of AEs. Published and
unpublished data from the EXPEDITE study [11] were
used to model these outcomes, as shown in Table 1. The
model’s sensitivity to key parameters was explored in
deterministic sensitivity analyses.
To ensure the model was representative of a UK NHS
hospital perspective, parameters to model labour man-
agement patterns–including the length and frequency of
vaginal examinations, vital signs monitoring and oxyto-
cin set-up carried out by midwives during pre-active and
active labour–were based on real-world clinical practice




In the base-case analysis, the model estimated an overall
28.9 % reduction in the time to vaginal delivery (27.8 %
and 30.8 % in nulliparous and parous women, respect-
ively) when using the MVI rather than the DVI. This
equated to an overall reduction of 10,201 h over one
Table 1 Model parameters informed by results from the EXPEDITE study (published [11] and unpublished data)
Model parameter DVI (n = 680) MVI (n = 678)
Clinical efficacy (published [11] and unpublished observations)
Median time to vaginal delivery per patient (hours) [11] 32.8 21.5
Mean time to vaginal delivery per patient (hours) 25.2 18.2
Proportion of women achieving vaginal delivery within 12 h (%) 10 21
Proportion of women achieving vaginal delivery within 24 h (%) 36 56
Proportion of women delivered by caesarean section due to a lack of efficacy (%) 2 1
Safety (unpublished observations)
Total adverse events (%) [11] 2.6 % 10.0 %
Uterine tachysystole without fetal heart rate involvement (requiring treatment) (%) 0.6 % 1.9 %
Uterine tachysystole with fetal heart rate involvement (late decelerations, bradycardia, or prolonged decelerations) (%) 1.2 % 6.0 %
Postpartum haemorrhage (%) 0.1 % 0.0 %
Meconium-stained liquor (%) 0.6 % 1.2 %
NICU admission (%) 0.1 % 0.6 %
Low Apgar score (%) 0.0 % 0.1 %
Uterine rupture 0.0 % 0.1 %
Neonatal acidosis (%) 0.0 % 0.1 %
Draycott et al. BMC Health Services Research  (2016) 16:49 Page 4 of 9year (Fig. 2), or a reduction of 7.3 h in the time to
vaginal delivery per induction (from 25.5 to 18.2 h).
A reduction in the proportion ofthe model cohort
experiencing prolonged labour (defined as >24 h) was
also estimated by the model; 68 % of women using the
DVI experienced prolonged labour, compared with 53 %
of women using the MVI. The proportional increase inTable 2 Resource utilisation parameters from Southmead
hospital
Model parameter Default value
Vaginal examinations (conducted by a midwife)
Duration of examination (minutes) 10
Frequency of examinations
Pre-active labour Once
Active labour (without oxytocin) Every 4 h
Active labour (with oxytocin) Every 3 h
Vital signs monitoring (conducted by a midwife)
Duration of monitoring (minutes) 3
Frequency of monitoring
Pre-active labour Every 4 h
Active labour–first stage Every 4 h
Active labour–second stage Every h
Oxytocin drip (set up by two midwives)
Time to set up oxytocin drip (minutes per midwife) 10
NICE clinical guidelines on intrapartum management [15] recommend
monitoring every four hours in the first stage of labour, followed by every
hour during the second stage. As the EXPEDITE study [11] did not stratify
active labour by stage, to replicate this pattern we assumed that the second
stage of labour stage would last no more than one hour, meaning one further
examination would occur during this timenulliparous women delivering vaginally within 12 and
24 h was higher than in parous women: the overall pro-
portion of women who delivered vaginally within 12 h
increased 1.9-fold in parous women (from 18.3 % to
35.6 % with the DVI and the MVI, respectively) and 3.6-
fold in nulliparous women (from 1.6 % to 5.9 %, respect-
ively), whilst the proportion of women delivering vaginally
within 24 h increased 1.3-fold in parous women (from
54.3 % to 70.0 %, respectively) and 2.1-fold in nulliparous
women (from 13.1 % to 27.1 %, respectively) (Fig. 3).
Use of the MVI rather than the DVI was associated
with an increase in treatment-related intrapartum AEs.
There were 36 AEs with the DVI compared with 140
with the MVI–an average of 0.07 additional AEs per
woman. The most common treatment-related AEs were
uterine tachysystole (defined as uterine activity of more
than five contractions in a 10-minute window, averaged
over three consecutive 10-minute periods) without fetal
heart rate involvement (i.e. requiring treatment) and
with fetal heart rate involvement (i.e. late decelerations,
bradycardia, or prolonged decelerations), which increased
3.2-fold and 5.0-fold, respectively (Fig. 4).
Of note, a post-hoc review of AE rates reported in the
EXPEDITE study was conducted by an independent,
blinded expert panel, which concluded that–despite the
higher incidence of certain AEs associated with the use of
the MVI–neonatal outcomes were not different between
the two treatment cohorts [11].
Resource utilisation
The estimated decrease in time to delivery associated
with use of the MVI compared with the DVI led to
Fig. 2 Time to vaginal delivery with the DVI vs the MVI
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estimated that 52 fewer midwife shifts were required
to handle the same number of labour inductions and
deliveries–a proportional reduction of 25.2 % (Fig. 5).
The model also showed that use of the MVI reduced
labour and delivery suite occupancy compared with the
DVI: over one year, an estimated 10,816 fewer bed hours
(or 451 bed days) within the labour and delivery suite
were required for women induced with the MVI rather
than the DVI, a decrease of 27.4 % (Fig. 6). Specifically,
6630 and 4186 h (or 277 and 174 bed days) were saved
for nulliparous and parous women, respectively. This
reduction in bed hours equates to nine and six hours
per nulliparous and parous woman, respectively.
In addition to decreased monitoring requirements due
to shorter length of time spent in labour, part of the
reduction in staff shifts was due to the decreased re-
quirement for oxytocin to augment labour induced with
the MVI. The annual number of shifts required to set up
oxytocin drips was one third lower when using the MVI
compared with the DVI (27 vs 43, respectively), and the
number of staff shifts required for vaginal examinationsFig. 3 Proportion of women achieving vaginal delivery within 12 and 24 hand vital signs monitoring in women requiring oxytocin
were halved (26 vs 53 and 6 vs 12, respectively).
As a result of these decreases in resource use associated
with MVI use, the model estimated that an additional 382
inductions per year could be accommodated with the
same resources if all women were induced with the MVI
instead of the DVI.
Births-per-midwife ratio
The reported births-per-midwife ratio at Southmead
Hospital is 33.0 (based on clinical opinion from lead
authors), with the recommended ratio at 29.5 [5]. The
27.4 % increase in capacity associated with using the
MVI instead of the DVI may translate into midwives,
assuming the number of labour inductions is constant,
having more time to manage for each birth, leading to
an estimated decrease in the births per midwife ratio
from 33.0 to 24.0.
Sensitivity analyses
One-way and multi-way sensitivity analyses were con-
ducted to test the robustness of staff capacity-focussedwith the DVI vs the MVI
Fig. 4 Proportion of women experiencing treatment-related AEs with the DVI vs the MVI
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the duration of vital signs monitoring, vaginal examinations
and oxytocin set-up, and frequency of vaginal examinations.
Changing the duration of all procedures had the largest
effect on the model results, but the reduction in midwife
shifts due to use of the MVI instead of the DVI remained;
the most conservative reduction (resulting from a scenario
in which the duration of all procedures increased by 50 %)
still yielded 25 fewer midwife shifts (Fig. 7).
Additionally, a scenario analysis was conducted to
estimate the impact of continuous monitoring, when
required, in women induced with the MVI; it was as-
sumed that continuous monitoring would entail staff
involvement equivalent to that associated with monitoring
women requiring oxytocin augmentation [29]. Despite the
continuous monitoring required for the MVI, decreased
time to delivery led to a 7.3 % decrease in midwife shifts,
or 30 fewer shifts, over one year.
Discussion
Main findings
Given current pressures on the NHS as a whole, and
with hospitals potentially lacking sufficient resources toFig. 5 Number of midwife shifts over one year with the DVI vs the MVImanage labour inductions and deliveries occurring in
the UK, the potential to alleviate some of the strain and
improve the efficiency and quality of care offered to
women with the same resources should be a key consid-
eration when making decisions regarding labour induc-
tion methods. Our model, based on data from real-life
clinical practice and a large clinical trial, demonstrates
that the MVI, by decreasing time to delivery compared
with the DVI, may have a positive impact on hospital
resource use and capacity. We estimate that using the
MVI, rather than the current recommended standard of
care, could reduce the number of midwife shifts required
for labour induction and delivery, as well as the level of
labour and delivery suite occupancy necessary to manage
labour-induced births. This is due to the reduced time
to active labour and vaginal delivery associated with the
use of the MVI compared with the DVI, which in turn
decreases the overall need for vital signs monitoring and
vaginal examinations–in particular due to a reduction in
the rate of, and duration of, oxytocin use (the adminis-
tration of which requires continuous monitoring to
check the progress of cervical ripening [12, 30]). A sce-
nario analysis showed that the reduction in resource use
Fig. 6 Hours of labour and delivery suite occupancy saved through the use of the MVI instead of the DVI
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required for the MVI.Strengths
Though efficacy and safety data for both vaginal inserts
were based on the EXPEDITE study [11] and unpublished
observations, respectively, actual data from Southmead
Hospital were used to inform both the demographics of
the modelled cohort of women and the estimation of
resource use associated with the management of labour
induction in the model. This is particularly crucial in view
of the expected deviation of actual practice from clinical
guidelines, and supports the relevance of our model’s
results to other UK hospitals.
Moreover, sensitivity analyses support the robustness
of our estimates, with the results remaining largely similar
throughout variation in the frequency and duration of
procedures by a magnitude of 50 %–no scenario reduced
midwife shift savings to fewer than 20 shifts. Given this,Fig. 7 Results of sensitivity analyses. VE = vaginal examination; VSM = vital
halving of parameterand despite the limitations discussed below, we expect
that the decreased resource use modelled using data from
Southmead Hospital would be applicable across various
NHS hospitals in the UK.
Limitations
Of course, a model-based approach is not a substitute
for clinical study–our model provides numerical estimates
of overall resource use based on key data from a number
of sources, but as with all model-based analyses, this is a
theoretical representation of what could potentially hap-
pen in actual patients. We must also acknowledge several
inherent limitations to our model, which could affect the
results reported here. Firstly, we do not consider the
financial impact of using the MVI instead of the DVI in
terms of drug costs. It must be noted, however, that drug
costs represent only 2 % of total labour induction costs
[31, 32], and that the majority of costs are incurred in
the management of labour. Therefore, savings may be
achieved through reductions in resource use. Nevertheless,signs monitoring, Increase = doubling of parameter; decrease =
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financial impact of using the MVI compared with the DVI.
In addition, the current model assumed that the second
stage of labour would last no more than one hour, despite
evidence to suggest that it may last longer in nulliparous
women [29]. However, as this would be true for all women,
regardless of their method of induction, we did not feel this
assumption would unduly favour either vaginal insert.
Another potential limitation of our model involves the
use of efficacy data from the EXPEDITE trial, which was
conducted in the US, to obtain UK-specific estimates.
There will of course be differences between a real cohort
of women in the UK and the US study population of the
EXPEDITE study–such differences must be considered
when forming conclusions from an theoretical analysis such
as this study. This highlights two important assumptions–
firstly, the similarity of the trial patient population to the
general population of expectant mothers within the UK,
and secondly how representative of UK clinical practice
results from a US-based trial are. In light of the first
assumption, while there will undoubtedly be differences
between the EXPEDITE study population compared to
an equivalent sample of women from the UK, the treat-
ment arms of the EXPEDITE study were well matched,
so we can assume that the differences would not differ
between induction methods (as they would apply to both
arms equally). Yet, we must acknowledge that there will
likely be differences–data collected from 75,397 pregnan-
cies at King’s College Hospital London (UK) [33] suggest
that characteristics of expectant mothers differ between
the UK and the EXPEDITE study population. This includes
a higher age of mothers at birth, a higher percentage of
parous pregnant women and a much lower proportion of
non-white pregnant women in the UK compared to the
EXPEDITE study population. Notably, the data col-
lected at a single hospital in the UK is not necessarily
fully translatable to the country-wide population, but
nonetheless serves as a good estimate with which to
represent a UK hospital population.
Regarding the second issue, it is well-known that clin-
ical practice in the management of labour, delivery and
AEs differs across countries, and more generally that
clinical trials are not representative of real-world practice.
However, certain trends (e.g. more frequent recourse to
caesarean sections [34]) would not affect the resource use
as estimated in our model, while parameters that would
affect our model (e.g. more stringent monitoring prac-
tices) would likely apply to all women regardless of their
method of induction. Moreover, the EXPEDITE study is
currently the only randomised clinical trial comparing the
MVI to the DVI in such a large patient population (over
1300 women), which supports the choice of this trial as
the source of clinical data for our model, and also the
validity of each drug’s efficacy in labour induction.Interpretation
The MVI is the only licensed misoprostol-based induction
method to be approved for use in labour induction, avoid-
ing any potential risks associated with off-label use. The
estimated reductions we report could lead to women be-
ing discharged from hospital and returning home sooner,
hypothetically increasing the birthing capacity of hospitals.
In reality, this increased capacity could allow existing
hospital resources to be freed–healthcare professionals
may subsequently allocate their time more effectively to
both induced and non-induced deliveries, especially in
women receiving oxytocin (potentially facilitating more
one-to-one care of these women, which is difficult to
achieve in practice despite being recommended in guide-
lines [7, 31]). This could ultimately lead to an improve-
ment in the quality of care received by women, as well as
improved performance and efficiency of maternity services
as a whole.
In line with results from the EXPEDITE study [11],
the model showed a 3.9 fold increase in the overall inci-
dence of treatment-related AEs associated with the MVI
(10.0 %) compared with the DVI (2.6 %; unpublished
observations from the clinical study report). The specific
resource use associated with managing these AEs was
not estimated in our model–while this is worth consider-
ing when estimating hospital-level resource use, methods
of managing these events are likely to differ between
hospitals and may fall within the care women are already
receiving throughout labour induction in the hospital.
However, published and unpublished results from the
EXPEDITE study show that the rate of NICU admissions,
caesarean sections and time to discharge after an AE with
the MVI was not significantly different compared with the
DVI [11], suggesting that the resource use associated with
managing AEs in both cohorts would not have differed
significantly. This is further supported by the similar rates
of AEs resolved without sequelae, and follow-up contact
due to hospital readmissions or accident and emergency
visits for both MVI-induced and DVI-induced women
(unpublished observations).
Conclusion
Maternity units in the UK must manage increasing birth
and labour induction rates during a period in which the
NHS faces cutbacks–this has the potential to overstretch
hospital resources. Resource use should therefore be
integral in the decision-making process regarding labour
induction methods. Our model-based analysis suggests
the MVI–the first misoprostol-based preparation to be
licensed for labour induction–is associated with a reduced
time to, and duration of, active labour compared to the
DVI, leading to an estimated reduced resource use in
terms of healthcare staff time and hospital bed hours.
In real-world practice, such a reduction in resource
utilisation could potentially translate into improved efficien-
cies and optimisation of patient care, without increasing the
burden on resources that hospitals already experience.
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